CN101613399B

CN101613399B - Surface protein of streptococcus suis type-2, preparation method thereof and application

Info

Publication number: CN101613399B
Application number: CN2008101155108A
Authority: CN
Inventors: 姜永强; 尉研; 耿红冉; 郑玉玲; 张炜; 李文君; 袁媛; 江华
Original assignee: Institute of Microbiology and Epidemiology of AMMS
Current assignee: Institute of Microbiology and Epidemiology of AMMS
Priority date: 2008-06-25
Filing date: 2008-06-25
Publication date: 2012-11-28
Anticipated expiration: 2028-06-25
Also published as: CN101613399A

Abstract

The invention discloses a surface protein of streptococcus suis type-2, preparation method thereof and application. The surface protein of streptococcus suis type-2 is numbered as gi|146321522 in genebank; the preparation method of the surface protein comprises the following steps: cloning gene of the surface protein; connecting the gene and expression plasmid of Escherichia coli to transform the Escherichia coli; inducing expressing; separating and purifying expression product; and the like. The surface lipoprotein can be used as a diagnostic target, and a specific antibody of the protein can be detected in animals and people infected with the streptococcus suis; moreover, the surface lipoprotein is also an important protective antigen, and can be used for preparing vaccines.

Description

A kind of streptococcus suis 2-type surface protein, Preparation Method And The Use

Technical field

The present invention relates to a kind of bacterium surface albumen, relate in particular to a kind of surface protein of streptococcus suis 2-type, also relate to this proteinic preparation method and purposes.

Background technology

Swine streptococcus (Streptococcus suis) belongs to the R crowd of Lan Shi classification, and 35 serotypes are arranged, and is popular the widest with streptococcus suis 2-type, pathogenic the strongest.After Denmark reported people's infection with streptococcus suis the earliest in nineteen sixty-eight, since the seventies in 20th century, the swine streptococcus case was all reported in American-European part country and area, Hong Kong, was main with meningitis mainly, and toxic shock syndrome (TSS) is rare, does not see outbreak of epidemic.China breaks out the people in 1998 and 2005 twice in Jiangsu and Sichuan and infects the streptococcus suis 2-type epidemic situation, and being different from state's stranger's cases of infection is main characteristics with the meningitis, and clinical manifestation is shock type and meningitis type.Most cases are died from toxic shock syndrome (TSS), and it is impaired that pathological change mainly shows as the many organs of whole body, septicemia companion disseminated intravascular coagulation (DIC).People's pig streptococcicosis has become a kind of new zoonosis of serious threat China people ' s health, and how effectively preventing and control streptococcus suis infection has become the research difficult problem that scientists faces.

Owing to understand very few to virulence factor and protective antigen; The bacterial strain of same serotype also is not quite similar in different regional virulence; Highly pathogenic streptococcus suis infection lacks the effective diagnosis target: such Pathogen Isolation is identified main rely on traditional separation and Culture and biochemical identification, carry out the agglutination test somatotype with the swine streptococcus hyper-immune serum then.But domestic animal is extensively carried suis, and many bacterial strain virulence are low, and it is far from being enough therefore only leaning on biochemical reaction to detect swine streptococcus, must set up the detection means to special virulence factor, to distinguish low virulent strain and virulent strain.Above situation has all hindered development and the timely diagnosis and the control to infecting of effective swine streptococcus disease vaccine.

Make a general survey of the development status of external swine streptococcus disease vaccine, mainly experienced full bacterial immunity and antigen protein two stages of immunity.The nineties in last century; There is the investigator to carry out intravenous injection and can stimulates antibody [the Holt ME that is produced conditioningization by immune swine with the swine streptococcus of Superlysoform deactivation; Enright MR, AlexanderTJ. (1990) Immunisation of pigs with killed cultures of Streptococcus suis type 2. Res Vet Sci.48:23-7].The investigator is also arranged through screening avirulent swine streptococcus two mutants; Wait the whole-bacterial-vaccine [KebedeM that obtains to have protectiveness like temperature-sensitive mutation body, streptomycin dependence two mutants; Chengappa MM; Stuart JG. (1990) Isolation and characterization oftemperature-sensitive mutants of Streptococcus suis:efficacy trial of the mutantvaccine in mice.Vet Microbiol.22:249-57.Foster N; Staats JJ; Chengappa MM. (1994) Isolation; Characterization and protection studies in mice of astreptomycin-dependent mutant of Streptococcus suis type 1/2.Vet Res Commun.18:155-63.], but the full bacterial immunity regular meeting of deactivation causes spinoffs such as immune syndrome.The follow-up investigator of having utilizes swine streptococcus to be correlated with virulence factor muramidase-released protein (MRP), extracellular factor (EF) combination water-in-oil emulsion (WO) and aluminum hydroxide adjuvant (AH) as vaccine; Its protectiveness and toxic side effect have been done evaluation; Find to have equal effectively anti--MRP and resist-the EF titre with the pig of MRP+EF/WO immunity and pig with full bacterium/WO immunity; And in the survival pig after immunity; Do not observe tangible clinical sign [Wisselink HJ; Vecht U; Stockhofe-Zurwieden N, Smith HE. (2001) Protection of pigs against challenge with virulent Streptococcus suis serotype 2strains by a muramidase-released protein and extracellular factor vaccine.Vet Rec.148:473-7.].The hemolysin (SLY) that the human purifying is also arranged is as vaccine immune mouse; Discovery can produce complete provide protection to mouse, avoids injury [Jacobs AA, the Loeffen PL of virulent strain; Van den BergAJ; Storm PK. (1994) Identification, purification, and characterization of athiol-activated hemolysin (suilysin) of Streptococcus suis.Infect Immun.62:1742-8.].But the virulence factor of swine streptococcus more often between since just demonstrate the relative diversity on the space-time; Though MRP, EF and virulence height correlation; But different with European pathogenic strain is that most Canadian pathogenic strains are not expressed MRP and EF, and the 2-type swine streptococcus deletion mutant of MRP and EF is the same with wild-type possesses virulence [Gottshalk M, Lebrun A equally; Wisselink HJ; Dubreuil JD, SmithHE, Vecht U. (1998) Production of virulence-related proteins by Canadian strainsof Streptococcus suis capsular type 2.Can J Vet Res 62:75-79.].China's epidemic strain and non-epidemic strain are all expressed MRP; And experimentation on animals shows that epidemic strain cultivation excretory supernatant does not cause pathology; The virulence factors such as MRP, EF, SLY of depending merely on existing understanding are not enough to explain the pathogenesis of China 2-type swine streptococcus, use MRP to produce in the antibody as people's immune vaccine and possibly be difficult to reach the ideal effect with MRP.And at home; The development of swine streptococcus vaccine also is in the starting state; Be deactivation whole-bacterial-vaccine [Wang Zhuo, Shu Xiuwei, Wang Wencheng. the optimization and the safety testing thereof of pig streptococcicosis bivalent inactivated vaccine candidate strain culture condition. the beastly magazine .38:34-36. of traditional Chinese medicines in (2004)].Therefore be necessary the practical situation according to China, development is fit to the new generation vaccine of the 2-type swine streptococcus of China, and excavating the new immunogenic virulence factor that has is the important channel of seeking new generation vaccine.

In general, surface exposure albumen and cell walls attachment protein often are used as the candidate's target and the serodiagnosis reagent of vaccine.Over nearly 10 years; Also there is the investigator to attempt to seek the candidate molecules of immunogenic swine streptococcus superficial cell wall-held protein as vaccine; Separation such as Haataja S in 1996 also identify a kind of semi-lactosi inhibition type adhesin, in the swine streptococcus of 23 kinds of serotypes, all can detect the existence of this adhesin with the method for immunoblotting; Discovery has very strong immunogenicity and conditioning functions; Be suitable as vaccine candidate molecule [Haataja S, Tikkanen K, Hytonen J; Finne J. (1996) The Gal alpha1-4 Gal-binding adhesin of Streptococcus suis, a gram-positivemeningitis-associated bacterium.Adv Exp Med Biol.408:25-34.].People such as Okwumabua O screened through the full genome to 2-type swine streptococcus in 2005; Find that a kind of molecular weight is a 38kDa albumen; Have good immunogenicity and protectiveness; Think that this albumen is vaccine candidate molecule and be suitable as the exploitation of diagnostic reagent preferably; This proteic biological function and with the relation of pathogenesis further [Okwumabua O, Chinnapapakkagari S. (2005) Identification of the gene encoding a 38-kilodalton immunogenic and protectiveantigen of Streptococcus suis.Clin Diagn Lab Immunol.12:484-90] in the research.

Summary of the invention

Have immunogenic virulence factor in order to seek, research and development swine streptococcus new generation vaccine the invention provides a kind of streptococcus suis 2-type novel surface albumen, also discloses the preparation method and its usage of this surface protein.The disclosed streptococcus suis 2-type surface protein of the present invention has the aminoacid sequence shown in the sequence 1 in the sequence table; The gene of this surface protein of encoding has the nucleotide sequence shown in the sequence 2 in the sequence table, and this proteic gene of encoding extensively exists in the streptococcus suis 2-type bacterial strain.This albumen called after SSU98_1675, genebank is numbered gi|146321522.

The invention also discloses the recombinant expression plasmid of expressing above-mentioned streptococcus suis 2-type superficial cell wall-held protein, it contains the nucleotide sequence of sequence 2 in the ordered list.Above-mentioned expression plasmid can be colibacillus expression plasmid, and concrete plasmid can be pET32a etc.

The invention also discloses the bacterial strain of the recombinant expression plasmid that contains above-mentioned expression streptococcus suis 2-type superficial cell wall-held protein, this bacterial strain is intestinal bacteria, can be the BL21 bacterial strain.

The invention also discloses the preparation method of above-mentioned surface protein, this method comprises the steps:

At first clone this surface protein gene: can carry out through PCR method, at first design synthetic primer, can add restriction enzyme site and protectiveness base at the primer two ends; Then according to PCR method; Template with the swine streptococcus preparation increases under certain condition, and amplified production is carried out agarose gel electrophoresis; And reclaim product and carry out enzyme and cut, confirm the surface protein gene.Be the recombinant plasmid preparation of expressing this surface protein gene then: the surface protein gene of preparation is connected with coli expression carrier; Expression vector can be prokaryotic expression carrier, can adopt commercial prokaryotic expression carrier, like coli expression carrier pET32a; The preparation expression vector; And transformed into escherichia coli, preparation reorganization bacterium utilizes bacterium colony PCR and restriction enzyme recombinate screening and the evaluation of bacterium; The reorganization bacterium is carried out the IPTG abduction delivering; Ultrasonic disruption reorganization bacterium is collected supernatant, carries out purifying with GE nickel affinity chromatography post.

The invention also discloses the purposes of above-mentioned surface protein.Surface protein of the present invention is the new immunogenicity antigen molecule of identifying through the immunoprotein group of 2 type swine streptococcus; Present result according to the swine streptococcus genome annotation; The prediction of this gene open reading frame is only arranged; The report that this albumen of Shang Weiyou is expressed in swine streptococcus does not have the clue of this gene function yet.

The present invention can be used as the diagnosis target through experiment showed, this albumen, in animal and human's serum of streptococcus suis infection, obviously rises to this proteic antibody, thereby can be used for developing the diagnostic reagent of streptococcus suis infection.The invention also discloses the application of surface protein in preparation streptococcus suis 2-type vaccine.Whole blood killing experiments through the immune serum of this protein Preparation is nursed one's health finds that this albumen has certain protection property, is new efficient protective antigen, can be used for preparing vaccine, as emphasis vaccine candidate and diagnosis molecule.

The present invention is accredited as the new immunogenicity antigen molecule of streptococcus suis 2-type with this surface protein first, and has prepared this surface protein and prepared corresponding antibodies through gene engineering method.And disclose this surface protein and can be used to prepare diagnostic reagent and the vaccine of swine streptococcus, aspect effectively prevention and control streptococcus suis infection, have excellent application value and vast market prospect.

Description of drawings

Fig. 1 is the purifying protein electrophorogram of streptococcus suis 2-type surface protein SSU98_1675, and wherein 3 is the LMWP standard, is followed successively by 97.4kDa from top to bottom, 66.2kDa, 43.0kDa, 31.0kDa, 20.0kDa; 1 is protein induced thing stoste before the last appearance, and 2 for the protein induced thing in last appearance back penetrates liquid, and 4-5 is the elutriant (not containing target protein) of 50mmol/L concentration imidazoles, and 6-8 is the elutriant (containing target protein) of 150mmol/L concentration imidazoles.

Fig. 2 is to the comparison of SSU98_1675 specific antibody.The antibody horizontal of patient and healthy subjects is (A) relatively, and the antibody horizontal before and after pig infects is (B) relatively.The ELISA experiment is used to estimate the special antibody response to SSU98_1675, and Trx (Trx) is as negative control.

Embodiment

Expression and purification and the Antibody Preparation of embodiment one streptococcus suis 2-type surface protein SSU98_1675

1. material and method

1.1 bacterial strain and plasmid

Streptococcus suis 2-type 98HAH12 strain [Chen C; Tang J; Dong W; Wang C, Feng Y, et al (2007) A Glimpse of Streptococcal Toxic Shock Syndrome from ComparativeGenomics of S.suis 2Chinese Isolates.PLoS ONE 2 (3): e315]; Escherichia coli DH5a, BL21 is the international standard strain; Expression vector pET32a (+) is the Novagen Company products.

1.2 enzyme and reagent

PCR agents useful for same such as restriction enzyme such as EcoRI and XhoI and Taq enzyme, dNTPs, DL15000 molecular weight standard are precious biotechnology (Dalian) ltd product; It is that the sky is Company products that DNA reclaims test kit; The nickel affinity chromatography post is the GE Company products; It is the V-gene Company products that plasmid extracts box; Freund's complete adjuvant and Freund's incomplete adjuvant are the Sigma Company products; Amp is middle promise medicine company product.

1.3PCR design of primers and SSU98_1675 nucleotide sequence, protein sequence

According to the fragment that will increase, design a pair of primer, the primer two ends are added EcoRI and XhoI restriction enzyme site and protectiveness base respectively, primer P1 and P2 streptococcus suis 2-type SSU98_1675 gene ORFs (ORF) the total length segment that can increase.Primer sequence is respectively:

Upstream primer P1:5 '-gcggatccaatagcaagattttttcgttgag-3 ' sees sequence 3 in the sequence table;

Downstream primer P2:5 '-gcctcgagctcactttctgttatctttttc-3 ' sees sequence 4 in the sequence table.

Nucleotide sequence＞SSU98_1675 sees sequence 2 in the sequence table, and aminoacid sequence＞SSU98_1675 sees sequence 1 in the sequence table.

1.4PCR amplification

Add the go forward side by side performing PCR amplification of each reactant successively by following order and condition.Streptococcus suis 2-type template DNA 2 μ L, 10 * buffer, 5 μ L, 2.5mmol/L dNTPs 3 μ L, each 1 μ L of primer P1 and P2 (5 μ mol/L), ddH2O 37 μ L, LA-Taq enzyme (5U/ μ L) 1 μ L.The condition of amplification is: 94 ℃ of 7min; 94 ℃ of 1min, 55 ℃ of 1min, 72 ℃ of 2min, 30 circulations; 72 ℃ of 7min.

1.5PCR the recovery and the enzyme of product are cut

The PCR product is at 1% agarose gel electrophoresis, and the back is reclaimed test kit with DNA and reclaimed the purpose fragment, and cuts 3h with BamHI and 37 ℃ of enzymes of XhoI.

1.6 construction of recombinant plasmid and evaluation

The single bacterium colony of DH5 α intestinal bacteria of pET32a empty plasmid is carried in inoculation in the LB meat soup that contains 100 μ g/mL Amp; After 37 ℃ of shakes are cultivated 12～16h; 1% switching is gone into 37 ℃ of shakes of fresh LB meat soup of 100 μ g/mL Amp and is cultivated 6h, with plasmid extraction test kit extracting plasmid.Behind BamHI and the Xho I double digestion, reclaim test kit recovery enzyme with DNA and cut product.The PCR double digestion is reclaimed product be connected with empty plasmid double digestion recovery product, and the DH5 α host bacterium of transformed competence colibacillus.The preparation of competence bacterium, transform and all to be undertaken, utilize bacterium colony PCR and digestion with restriction enzyme recombinate screening and the evaluation of bacterium by ordinary method.

1.7 the order-checking of recombinant plasmid and sequential analysis

The sequencing of recombinant plasmid adopts the terminal cessation method of the two deoxidations of Sanger, and three rich polygala root Bioisystech Co., Ltd accomplish by Beijing, verifying its reading frame, and carries out homology analysis with BLAST software.

1.8 expression and the purifying of recombinant plasmid in intestinal bacteria

Recombinant plasmid by the e. coli bl21 of ordinary method transformed competence colibacillus, is utilized Amp resistance screening reorganization bacterium, choose in single colony inoculation LB meat soup and (contain 100 μ g/mL Amp), 30 ℃ of violent shakes are cultivated 2～4h, as bacterial concentration OD ₆₀₀Reach at 0.5～0.6 o'clock, add IPTG to final concentration 1mmol/L, 30 ℃ are continued violent shake and cultivate 2～4h.The centrifugal 10min of 6000r/min precipitates resuspendedly with zero(ppm) water, adds isopyknic 2 * electrophoresis sample-loading buffer and boils 10min, and SDS-PAGE detects.Also equally after IPTG induces processing, SDS-PAGE detects expression to the e. coli bl21 that contains sky pET32a (+).With ultrasonic disruption inductive reorganization bacterium, collect supernatant, carry out affinity chromatography with GE nickel affinity chromatography post, concrete steps are undertaken by working instructions.

1.9 recombinant protein animal immune test

The albumen of collecting is diluted to 0.1mg/ml with the PBS of PH7.210mmol/L, adds the Freund's complete adjuvant of equivalent, subcutaneous immune Wistar rat (available from Military Medical Science Institute experimental animal center), 0.5ml/ is only; Later on 3-5 week, respectively with 0.2,0.4,0.8,1.6mg/ml adds the Freund's incomplete adjuvant booster immunization, and the docking of the 7th week is got blood ELISA method and surveyed antibody titer.Set up full bacterial immunity control group and blank group (the pET32a empty plasmid transforms BL21, and abduction delivering Trx albumen is blank with this protein immunization rat) simultaneously.Prepare antiserum(antisera) with ammonium sulfate precipitation method.

2. result

2.1PCR result

The PCR product band of a treaty 2178bp occurs behind electrophoresis, size is consistent with expection.

2.2 the evaluation of recombinant plasmid

The SSU98_1675 gene fragment is through reclaiming, with BamHI and Xho I restriction enzyme site directed cloning to pET-32a, acquisition recombinant plasmid, called after SSU98_1675-pET-32a.The DH5 α host bacterium of recombinant plasmid transformed competence colibacillus obtains the bacterium of recombinating through the Amp resistance screening.Extract recombinant plasmid,, can cut out the segment about about 2178bp, explain that the SSU98_1675 fragment successfully clones through EcoRI and Xho I double digestion.

2.3 the expression of recombinant plasmid

Reorganization BL21 transformed bacteria is after IPTG induces, and thalline SDS-PAGE shows the protein band of a 97kD, and contain bacterium before inducing at this place no specific band.Obtain the SSU98_1675 albumen of purifying through ni-sepharose purification.See Fig. 1.

2.4 sequencing result and sequential analysis

Clone's sequence length for 2178bp, shown in sequence in the sequence table 2, is 725 amino-acid residues after the translation through order-checking, sees sequence 1 in the sequence table.

The immunogenicity of embodiment two streptococcus suis 2-type surface protein SSU98_1675 and antibody-mediated opsono-cytophagic test

1. material method: material is with embodiment one.

1.1 reorganization streptococcus suis 2-type surface protein SSU98_1675 and many anti-preparations: see embodiment one.

1.2SSU98_1675 antibody-mediated opsonophagocytosis

Blood agar is scraped and is got streptococcus suis 2-type list bacterium colony, inserts the THB substratum, and 37 ℃, CO ₂The fresh THB culture medium culturing 8h of switching was to logarithmic phase after incubator was cultivated 8h.Get 1ml bacterium liquid (about 1 * 10 ⁸CFU/ml) 13,000rpm, 1min collection bacterium, PBS washes bacterium and resuspended, is adjusted to 10 ⁶CFU/ml is coated with blood agar, is designated as initial bacterium amount.(≈ 10 to get 50 μ l ⁶CFU/ml) bacterium liquid adds 100 μ l antibody, 15min on ice behind 37 ℃ of 15min; Add 37 ℃ of 350 μ l healthy subjects whole bloods, 3h; Add 55 μ l 1%saponin, 20min on ice; The dilution of piping and druming back is coated with blood agar repeatedly, blood agar numeration mono-clonal behind the 16h.

1.3 infected pigs and philtrum SSU98_1675 albumen specific antibody are measured

Adopt in EUSA (ELISA) mensuration patient and the infection animal and be directed against this proteic specific antibody, adopt the serum of healthy subjects and infect preceding animal serum as contrast.Adopt the recombinant protein of 5 μ g/ml to encapsulate elisa plate, encapsulating damping fluid is 0.05M NaHCO ₃(PH 9.6), 4 ℃ encapsulate and spend the night, and adopt 37 ℃ of sealings of 3%BSA 3h then.The dilution in 1: 500 of patient and healthy subjects serum sample, porcine blood serum dilution in equal 1: 200 before and after infecting, reaction signal is through two anti-detections of horseradish peroxidase (HRP) mark.

2. result

2.1 the conditioning phagocytosis that recombinant protein is antibody-mediated

Obtain purified recombinant Protein S SU98_1675 through GE nickel affinity chromatography column chromatography, add respectively Fu Shi fully with the Freund immunity after, prepare antiserum(antisera), carry out indirect BA.Sterilizing rate calculates: (CFUrTrx-CFUr98_1675)/and CFUrTrx.Trx is the Trx from the e. coli bl21 ni-sepharose purification that contains pET32a (+) empty carrier.

Antibody-mediated opsono-cytophagic test: use the SSU98_1675 recombinant protein respectively; Rat blood serum behind the MRP recombinant protein immune rat is nursed one's health healthy human blood, carries out the fragmentation test of people's whole blood to the streptococcus suis 2-type viable bacteria.The antiserum(antisera) conditioning human whole blood of SSU98_1675 recombinant protein is about 50% to the kill rate of streptococcus suis 2-type, but a little less than the proteic antiserum(antisera) of MRP, the proteic antiserum(antisera) conditioning human of MRP whole blood is 90% to the kill rate of streptococcus suis 2-type.

2.2 the SSU98_1675 specific antibody detects in people who infects and the porcine blood serum

The present invention has detected the situation that exists of SSU98_1675 specific antibody in patient that 6 streptococcus suis 2-types infect and 5 the healthy subjects serum, and the result finds to compare with healthy subjects, and patient SSU98_1675 specific antibody level obviously raises, see Fig. 2 A.We have detected before and after the streptococcus suis 2-type infected pigs situation that exists of SSU98_1675 specific antibody in the serum, the result find with infect before compare, infect that SSU98_1675 specific antibody level significantly raises in the serum of back, see Fig. 2 B.Above-mentioned experimental result shows that SSU98_1675 can be used as the diagnosis target and is used for the serodiagnosis that streptococcus suis 2-type infects.

Pig chain 2 type surface protein 1675.SEQ

Sequence table

< 110>Inst. of Epidemiology and Microbiology, Academy of Military Medical Sciences, PL

< 120>a kind of streptococcus suis 2-type surface protein, Preparation Method And The Use

<130>

<160>4

<170>PatentIn version 3.2

<210>1

<211>725

<212>PRT

<213>

<400>1

Met Asn Ser Lys Ile Phe Ser Leu Arg Lys Ser Lys Met Gly Leu Val

1 5 10 15

Ser Val Ala Ile Ala Phe Leu Trp Ile Gly Thr Gly Met Asn Met Glu

20 25 30

Thr Ala Met Ala Glu Glu Thr Asp Ala Thr Ala Leu Glu Thr Gln Leu

35 40 45

Glu Ser Thr Glu Ser Ser Leu Thr Asn Thr Val Ser Glu Asn Ala Glu

50 55 60

Ala Glu Glu Val Ala Asp Glu Val Pro Ser Glu Glu Lys Lys Ser Glu

65 70 75 80

Glu Met Glu Asp Met Glu Glu Glu Leu Ser Phe Ile Glu Asn His Leu

85 90 95

Glu Val Ala Pro Ile Gln Ala Gly Asp Gln Thr Ile Ser Gly Asn Thr

100 105 110

Thr Pro Gly Gly Tyr Val Ala Ile Thr Ile Asp Gly Glu Ala Ile Thr

115 120 125

Ser Ile Glu Asn Ile Leu Glu Ala Asp Asp Lys Gly Asp Phe Ser Tyr

130 135 140

Arg Leu Ser Lys Pro Leu Ala His Ser Gln Thr Val Glu Ile Ser Ala

145 150 155 160

Leu Pro Lys Gln Phe Trp Thr Leu Glu Ala Asp Ser Glu Glu Arg Lys

165 170 175

Val Val Val Arg Thr Asn Arg His Pro Glu Ala Tyr Glu Ile Pro Ala

180 185 190

Lys Arg Leu Glu Lys Thr Ser Asn Gly Met His Gln Val Phe Ile Glu

195 200 205

Pro Val Phe Glu His Thr Ser Lys Val Ile Gly His Thr Ser Val Lys

210 215 220

Gly Ser Val Tyr Leu Ser Ile Asn Gly Ser Phe Val Ser Asp Lys Thr

225 230 235 240

Leu Ile Asp Pro Lys Asp Gly Arg Phe Glu Val Thr Phe Ser Glu Ser

245 250 255

Leu Ala Gly Ser Lys Phe Lys Ala Asp Asp Arg Leu Val Leu Ser Phe

260 265 270

Val Ser Glu Asp Gly Gln Pro Val Ile Thr Asn Thr Ile Val Lys Pro

275 280 285

Leu Val Lys Glu Lys Val Ser Ser Gln Met Thr Val Lys Pro Leu Ser

290 295 300

Ser Ala Thr Ser Val Leu Glu Gly Thr Thr Phe Pro Leu Gly Arg Val

305 310 315 320

His Leu Tyr Asn Ala Asp Thr Ser Glu Phe Ile Met Glu Ala Ile Ala

325 330 335

Asp Glu Thr Gly His Tyr Lys Ile Ala Leu Pro Ala Leu Gln Ser Glu

340 345 350

Asp Lys Tyr Tyr Arg Leu Thr His Asn Gln Gln Glu Asp Leu Val Ser

355 360 365

Val His Leu Asp Thr Val Asp Gly Ser Ser Ile Leu Leu Asp Lys Ser

370 375 380

Val Met Ala Ser Leu Ala Thr Tyr Leu Gln Asp Ala Asp Met Asp Glu

385 390 395 400

Ala Thr Asp Glu Asp Pro Ile Ile Val Pro Lys Leu His Asn Lys Lys

405 410 415

Asp Tyr Ile Val Gly Arg Thr Ile His Leu Asn Ala Tyr Val Arg Met

420 425 430

Val Ser Ser Ile Lys Gly Lys Gln Tyr Pro Pro Val Gln Val Asp Glu

435 440 445

Leu Gly Phe Phe Gly Phe Gln Ile Gln Asp Leu Gln Leu Pro Phe Glu

450 455 460

Lys Gly Glu Arg Ile Arg Phe Glu Ile Ile Asp Pro Val Thr Asn Asn

465 470 475 480

Ile Ile Ala Ser Lys Glu Glu Val Val Gly Gln Tyr Leu Glu Asp Glu

485 490 495

Asp Val Met Asp Leu Pro Phe Gln Val Glu Lys Val Thr Thr Asp His

500 505 510

Gly Tyr Ile Ser Gly Lys Thr Ala Pro Asp Val Met Ile Glu Leu Val

515 520 525

Ser Thr Gln Asn Gly Glu Glu Ile Ile Gly Lys Thr Ser Thr Asp Ser

530 535 540

Thr Gly Arg Phe Glu Phe Asp Leu Gly Ser Arg Val Leu Lys Asn Gly

545 550 555 560

Glu Thr Leu Ser Phe Arg Ala Phe Asp Lys Glu Gly Glu Gln Val Ala

565 570 575

Trp Glu Val Val Thr Val Gln Lys Gly Asn Gly His Arg Ile Asn Lys

580 585 590

Pro Asp Lys Lys Asp Glu Lys Glu Glu Gln Pro Ser Lys Glu Ile Thr

595 600 605

Lys Asn Ile Glu Gln Ser Asn Thr Leu Glu Gln Thr Thr Leu Pro Pro

610 615 620

Val Arg Gln Thr Leu Thr Asp Lys Lys Val Glu Gln Asn Ala Glu Pro

625 630 635 640

Ser Lys Glu Glu Thr Val Ser Ile Phe Asp Asp Ser Lys Lys Asp Met

645 650 655

Pro Thr Lys Gln Glu Lys Met Ala Arg Thr Val Arg Asp Lys Gly Thr

660 665 670

Lys Gly Asn Val Ser Val His Asp Ser Gly Glu Asn Thr Gln Val Gln

675 680 685

Ser Leu Pro Lys Thr Gly Glu Lys Thr Ser Leu Val Ala Asn Ile Met

690 695 700

Leu Ser Ile Ile Leu Phe Leu Phe Ala Leu Phe Ile Gly Lys Lys Lys

705 710 715 720

Ile Thr Glu Ser Glu

725

<210>2

<211>2178

<212>DNA

<213>

<400>2

atgaatagca agattttttc gttgagaaaa agtaagatgg gtttagtttc ggtggcaatt 60

gcttttctat ggattggtac agggatgaat atggaaaccg caatggctga ggagactgac 120

gctacagctc ttgaaactca attagaaagc acggaatcat cgcttaccaa tacagtttcg 180

gaaaatgctg aagctgagga agtggctgat gaggtaccga gtgaagaaaa aaaatcggaa 240

gagatggagg atatggagga agaactttca tttattgaaa accatctaga ggttgctccg 300

attcaagctg gagatcaaac catctcaggg aataccactc ctggtggata tgtagcgatt 360

acgatagatg gggaagcaat tacttctatt gagaatattt tggaagcaga tgataaggga 420

gatttttctt atcggttgag taaaccactt gctcacagcc aaactgtgga aattagtgct 480

ttgccgaaac agttttggac tctagaggca gattctgaag agcgtaaggt agtagtgagg 540

actaatcgac atccagaggc ttatgaaatt ccagcaaaaa gattagaaaa aacatctaat 600

ggaatgcatc aagtgttcat cgaaccagtt tttgaacata cgagcaaagt tattggtcat 660

acctctgtca aaggttcagt ctatctatca ataaatggta gttttgtctc tgataagaca 720

ctaattgatc ctaaagatgg acggtttgag gttacttttt ccgagagttt agcaggttca 780

aaatttaaag cagatgatag attggttttg tcttttgtat cagaagatgg tcagccggtg 840

attactaata ctattgtaaa accattggta aaagaaaaag tatcttcaca aatgacagta 900

aaacctttat caagtgcgac ttcagttttg gaaggaacta catttccttt aggtcgtgtg 960

catctataca atgctgatac ttcagagttt atcatggaag ctattgctga tgagacaggt 1020

cactataaga ttgctttgcc tgccctacaa tccgaggata agtactacag attgactcac 1080

aatcaacaag aggacttggt atctgtccat cttgatacag ttgatggttc aagtatatta 1140

ttggataaat ctgttatggc atctttagca acttatttac aagatgcaga tatggatgaa 1200

gcgacagatg aagatcctat cattgtacct aaactgcata ataaaaaaga ttatattgtc 1260

ggtcgaacga tacatcttaa tgcctacgtt cgcatggttt cgtcaatcaa aggaaaacag 1320

tatcctccag ttcaagtgga cgaattagga ttttttggtt tccaaattca agatttacaa 1380

ttgccttttg aaaaaggtga gagaattcgc tttgaaatca ttgacccggt tacaaataat 1440

atcatcgcta gtaaggaaga agttgtaggg caatatttgg aagatgaaga cgtgatggat 1500

ttaccatttc aagtagaaaa agtcactaca gatcatggtt acatcagtgg caaaacagct 1560

ccagatgtaa tgattgaact agtatcaact cagaatggcg aggagataat tggtaaaact 1620

tcaactgatt caacaggtcg attcgaattt gatttgggta gtcgtgtttt aaaaaatgga 1680

gaaaccttat cgtttagagc gtttgataaa gaaggtgaac aggtagcttg ggaagtcgta 1740

acggttcaaa aaggaaatgg tcaccgcatt aataaaccag ataaaaagga cgagaaggaa 1800

gagcaaccta gcaaagaaat taccaaaaat atcgaacaat caaacacact tgagcaaact 1860

actttgccac ctgtacgcca aacgctgact gacaaaaaag tagagcaaaa tgcagagcca 1920

tcaaaagaag aaacggtttc tatttttgat gattcgaaaa aagatatgcc tactaagcaa 1980

gagaaaatgg ctcgtactgt aagagacaaa gggacaaaag gaaacgtatc tgtgcatgat 2040

agtggtgaga atacccaagt tcaaagcctg cctaagaccg gtgaaaaaac gagcttggtt 2100

gccaatataa tgttatcgat catattattc ttatttgctt tattcattgg caagaaaaag 2160

ataacagaaa gtgagtaa 2178

<210>3

<211>31

<212>DNA

<213>

<400>3

gcggatccaa tagcaagatt ttttcgttga g 31

<210>4

<211>30

<212>DNA

<213>

<400>4

gcctcgagct cactttctgt tatctttttc 30

Claims

1. streptococcus suis 2-type surface protein, it is characterized in that: its aminoacid sequence is shown in sequence in the sequence table 1.

2. according to the streptococcus suis 2-type surface protein of claim 1, it is characterized in that: its encoding sox is shown in sequence in the sequence table 2.

3. recombinant expression plasmid of expressing the streptococcus suis 2-type surface protein is characterized in that containing the nucleotide sequence of sequence 2 in the ordered list.

4. recombinant expression plasmid according to claim 3, wherein expression plasmid is colibacillus expression plasmid pET32a.

5. a bacterial strain of expressing the streptococcus suis 2-type surface protein is characterized in that containing the said recombinant expression plasmid of claim 3.

6. according to the said bacterial strain of claim 5, wherein expression strain is an e. coli bl21.

7. the preparation method of claim 1 or 2 said streptococcus suis 2-type surface proteins comprises the steps:

(1) clones this surface protein gene;

(2) gene is connected transformed into escherichia coli with colibacillus expression plasmid;

(3) abduction delivering;

(4) expression product is carried out separation and purification.

8. according to the said method of claim 7, wherein colibacillus expression plasmid is pET32a, and intestinal bacteria are E.coli BL21.

9. claim 1 or the 2 described streptococcus suis 2-type surface proteins application in preparation streptococcus suis 2-type infection diagnostic reagent.

10. claim 1 or the 2 described streptococcus suis 2-type surface proteins application in preparation streptococcus suis 2-type vaccine.